Company ProfilePremium

HKE Holdings Limited

Company Profile Analysis

Ticker: 1726.HK

ESOMAR 23 Corporate BadgeISO Certifications Badge
HKE Holdings Limited - Company showcase

Year Founded & Workforce

1979

103 Employees

HKE Holdings Limited logo

HKE Holdings Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

HKE Holdings Limited Overview

HKE Holdings is a micro-cap hybrid that combines a profitable but small Singapore healthcare-construction niche with a loss-making Hong Kong financial-services venture. The core operating asset, Hwa Koon Engineering, is a specialist contractor for hospitals and clinics in Singapore. It has expertise in radiation-shielding works for diagnostic-imaging and radiotherapy rooms and delivers integrated design-and-build fit-outs plus maintenance. Since Mr. Lin Ho Man took control in 2021, the Group has spent heavily to build a Hong Kong virtual-asset platform. That platform is operated by Hong Kong BGE Limited, which received an SFC VATP licence on 17 June 2025, and it sits alongside an SFC-licensed advisory, asset-management and OTC-derivatives arm. Group losses have run at S$11–15 million a year since FY2022 and were funded through repeated equity placings. On 29 September 2026 management agreed to sell the FinTech Platform Business to entities linked to the controlling shareholder. That decision redirects the Group toward trading/asset management, healthcare and AI-related "asset-light" opportunities.


Company's own description (paraphrased from the FY2026 results announcement, MD&A)

The Group describes itself as a specialist contractor in the medical and healthcare sector with expertise in radiation-shielding works. It mainly provides integrated design and building services for hospitals and clinics in Singapore, which it calls the Engineering Business, and to a lesser extent maintenance and other services. From May 2021 it built a multi-asset FinTech service platform covering virtual assets, listed securities, listed bonds and alternative assets. Through two subsidiaries it also trades derivatives and provides advisory and asset-management services, which it calls the Trading and Asset Management Business. The stated aim of that arm was to diversify income and offer a full spectrum of financial services.

Operating segments (FY2026 definition)

  1. Engineering Business. Integrated design and building services for healthcare facilities, including radiation shielding, M&E works and fitting-out, plus maintenance and other services and historically sales of tools and materials. Delivered in Singapore.

  2. FinTech Platform Business. Virtual-asset trading platform services via Hong Kong BGE Limited. Its revenue was historically from virtual-asset custodian solutions via BGC Limited and BG Technologies Limited. This segment is to be disposed of under the agreements of 29 Sep 2026.

  3. Trading and Asset Management Business. OTC derivatives trading (unlisted options and total return swaps), hedging services, asset management, and investment advisory/research support. It is run through Monmonkey Group Asset Management Limited (SFC Type 4 and Type 9) and Quality Union Limited.

  4. Others. Investment holding and property investment, which sit below the reportable thresholds. Before FY2026 this was presented as an "Investment Holding" segment.

Revenue model and mix

Revenue stream (SGD Mn)FY2022FY2023FY2024FY2025FY2026
Integrated design and building services (S$ M)9.62012.11616.13120.48517.740
Maintenance and other services (S$ M)0.4290.7421.0181.0520.781
Virtual assets custodian solutions (S$ M)00.5850.31300
Asset management services (S$ M)000.3140.5740.933
Investment advisory and research support (S$ M)00000.131
Hedging services income (S$ M)0000.0600.004
Commission, handling and fee income (S$ M)000.01800.002
Net trading income, IFRS 9 (S$ M)000.6390.8070.087
Total revenue (S$ M)10.04813.44318.43322.97719.679

Sources: FY2023, FY2024 and FY2026 results announcements, Note 5.

The model is project-based contracting with fixed-price contracts, which the filings say typically run one year or less. Revenue is recognised over time (S$18.8 million in FY2026) or at a point in time (S$0.8 million in FY2026). The Group has essentially no subscription or licensing revenue. The FinTech platform's fee revenue was negligible, at S$2,136 in FY2026. Financial-services revenue is a blend of fee income and trading P&L, and the trading P&L is volatile.

Value-chain position, customers and end-markets

In engineering, HKE operates as a specialist sub-contractor or turnkey contractor in hospital and clinic construction and refurbishment. It sits between medical-equipment vendors (CT, MRI, linear accelerators), main contractors and healthcare owners (public healthcare clusters and private hospital groups). Subcontractor costs were S$5.95 million in FY2026, which suggests an asset-light delivery model.

Customer concentration is extreme. In FY2026, four customers each exceeded 10% of revenue and together accounted for S$14.39 million, or about 73% (analyst-computed from FY2026 Note 5). Concentration was about 63% in FY2025, 48% in FY2024, 55% in FY2023 and 73% in FY2022.

Financial-services customers include institutional and professional clients. Material flows go through the connected brokerage Monmonkey Group Securities Limited (MMK), founded by the Chairman, which is the hedging-services counterparty and the planned anchor VATP client.

Independent characterisation

HKE is best understood as two businesses with opposite economics:

The engineering arm: is a small, cash-generative niche contractor. It turned in S$10–22 million of revenue and positive segment results every year FY2022–FY2026, but its segment margin compressed sharply from 22% in FY2022 to 0.4% in FY2026.

The FinTech arm: burned S$9–12 million a year in segment losses from FY2022 to FY2026, about S$55 million cumulatively (analyst-computed), and produced trivial revenue. In FY2026 its operating costs were about 45% of group administrative expenses, per the MD&A.

The Group's equity story since 2021 has rested on the FinTech option value, and the September 2026 decision to exit it marks a strategic reversal.

Strategy

Stated strategy (themes paraphrased from the FY2026 results announcement)

  1. Exit the capital-intensive FinTech platform. Management concluded that structural crypto-market volatility and tighter licensing standards cloud the platform's growth outlook. FinTech costs were about 45% of group administrative expenses with no meaningful revenue since licensing, so management decided to dispose of it to protect group finances and shareholders' long-term interests.

  2. Redeploy freed capital and management attention mainly into the Trading and Asset Management segment.

  3. Diversify into sustainable-growth areas. The Group is evaluating projects in AI-related fields, healthcare and other efficient asset-light applications, with a stated balance between expansion and risk control.

  4. Defend and grow the Singapore healthcare-construction niche. The thesis rests on Singapore's ageing population and the Ministry of Health facility pipeline, the Group's involvement in planning a new eastern hospital, entry into MRI-room shielding, and equipment replacement and pandemic-readiness upgrades.

Strategic initiatives in the last 24 months (Oct 2024–Oct 2026)

InitiativeDateDetailStatus
Convertible bond financingJan–Feb 2025HK$26 million zero-coupon CB; 80% of proceeds to FinTech, 20% to working capitalFully utilised by 30 Jun 2026
BGE VATP licensing17 Jun 2025SFC Type 1, Type 7 and AMLO VATP licencesAchieved; platform launched Jan 2026
Shareholder loan facilityJun 2025About US$10 million from Lin Ho Man at 2.5%; US$8.5 million outstanding at 30 Jun 2026Due 15 May 2027 (extendable one year)
2026 placingFeb 202664 million shares at HK$1.20; net HK$76.0 million split 55% FinTech, 35% strategic equity investment, 10% working capitalHK$32.8 million of FinTech funds deployed; HK$26.6 million for strategic investment unutilised at 30 Jun 2026 (expected by 31 Dec 2026)
BG Ventures strategic investmentFeb 2026 agreement; Aug 2026 completionAbout RMB60 million for 2.29% of an unnamed investee, via a partly-owned subsidiary with outside NCI capitalCompleted
MMK VA cooperation framework29 May 2026 circular; 22 Jun 2026 EGMBGE to provide platform and OTC services to MMK, with Quality Union as sole OTC liquidity provider through 30 Jun 2029; caps assume 100% annual VA volume growth from about US$313 millionEGM held; poll results published 22 Jun 2026. Now likely superseded by the disposal
FinTech disposal29 Sep 2026Sale of True Victor (HK$250.3 million total consideration including assignment of a HK$145.4 million shareholder loan) and Wonder Time (HK$0.5 million including a HK$189.5 million loan) to Finfra Holdings and Nexafin Investment, both connected to LinPending independent shareholder approval; circular due by 31 Oct 2026
Cost programmeFY2026Administrative expenses cut 9.8% (S$2.3 million); headcount −10Delivered; no forward numeric target disclosed
ESGAnnualESG report included in annual reportsNo quantified targets identified

Medium-term financial targets and guidance

Not publicly disclosed. Management provides qualitative outlook only and no revenue, margin or profitability targets.

Products & Services

Engineering Business (Hwa Koon Engineering Pte. Ltd., Singapore)

OfferingDescriptionTarget customerPricing modelStatus / evidence
Radiation-shielding worksDesign and construction of shielded rooms for X-ray, CT, nuclear medicine, linear accelerators and similarPublic hospitals, polyclinics, private hospitals, imaging centresFixed-price contracts, typically ≤1 yearCore competence per every MD&A FY2022–FY2026
MRI room shielding (RF shielding)New-market entry targeting MRI suites; management notes MRI waiting times of about 3 monthsHospitals adding diagnostic imaging capacityFixed-priceStated as an intended market entry in the FY2026 MD&A; no revenue disclosed
Integrated design-and-build ("turnkey")Combined design, radiation shielding, M&E and fitting-out for healthcare spacesHealthcare owners and main contractorsFixed-price, recognised over timeLargest revenue line: S$17.7 million in FY2026
M&E worksMechanical and electrical installation within healthcare fit-outsAs aboveWithin project priceThird-party profiles (Simply Wall St); bundled in integrated services
Fitting-out worksInterior fit-out of clinical spacesAs aboveWithin project priceThird-party profiles
Maintenance and other servicesPost-completion maintenance and minor worksExisting facility ownersPoint-in-time / serviceS$0.78 million in FY2026
Sales of tools and materialsAncillary product salesContractorsPoint-in-timeDisclosed in FY2024/FY2025 segment definitions; immaterial
New-hospital planning involvementParticipation in planning a new hospital in eastern SingaporePublic healthcare—FY2024 and FY2026 MD&A

FinTech Platform Business (to be disposed)

OfferingEntityDescriptionLicence / launchPricing
BGE virtual-asset trading platformHong Kong BGE LimitedSFC-licensed spot VA exchange (order book) for selected virtual assetsSFC Type 1, Type 7 and AMLO VATP licences, 17 Jun 2025; official launch Jan 2026Trading fees; FY2026 fee income S$2,136
BGE OTC trading deskHong Kong BGE LimitedLicensed OTC execution for large or customised VA trades, offered as a complement to the order bookPart of the VATP licence scope (HKEX, 16 Feb 2026)Spread or fee; not disclosed
VA custodyBGE (as VATP) / formerly BGC LimitedCustody of client virtual assets and client money as required by VATP rulesBGC holds a TCSP licence (FY2023 MD&A)—
Virtual-asset custodian solutions (wallet services)BGC Limited, BG Technologies LimitedWallet-service custody modelLaunched FY2023; revenue S$0.585 million in FY2023 and S$0.313 million in FY2024, nil thereafterWallet service fees
Market data services and trading systemsGroup FinTech subsidiariesMarket data, analytics, order-management and risk-management systems for equitiesMarket Data Vendor Licence approved by HKEx Information Services (FY2023 MD&A)Not disclosed; no revenue reported
Planned VA services to MMKBGE (platform/OTC) with Quality Union as sole OTC liquidity providerFramework running 1 Jul 2026 to 30 Jun 2029, subject to approvalsEGM 22 Jun 2026Caps based on MMK's VA volume of about US$313 million (Mar 2025–Feb 2026)

Trading and Asset Management Business

OfferingEntityDescriptionLicenceFY2026 revenue (SGD)
Asset managementMonmonkey Group Asset Management LimitedManagement fees from managed fundsSFC Type 4 (advising on securities), Type 9 (asset management)932,698
Investment advisory and research supportMonmonkey Group Asset ManagementAdvisory and research-support feesType 4131,486
Hedging services (OTC swaps)Quality Union LimitedOTC swap trades with clients and related party MMK, under IFRS 15—4,437
Proprietary and client-facing OTC derivativesQuality Union LimitedUnlisted options and total return swaps; IFRS 9 net trading incomeNot disclosed (SFC VA authorisation for QUL was pending in 2026)86,983

Others / Investment holding

Hong Kong investment properties: fair value S$4.04 million at 30 Jun 2026, down from S$5.25 million at 30 Jun 2022. Rental income was S$0.12 million in FY2026, and fair-value losses ran S$0.20–0.33 million a year in FY2024–FY2026.

BG Ventures Capital Limited: (partly owned): 2.29% stake in an unnamed independent investee for about RMB60 million (≈S$11.4 million), completed August 2026. Non-controlling interests rose to S$5.51 million at 30 Jun 2026.

Cryptocurrency holdings: S$0.82 million at 30 Jun 2026 (S$1.31 million a year earlier).

Financial Narrative

All figures are S$ millions for fiscal years ended 30 June. Sources: FY2023, FY2024 and FY2026 results announcements, which contain FY2022–FY2026 audited figures. Cash flow data for FY2022–FY2025 is from S&P Global Market Intelligence via StockAnalysis. The FY2026 cash flow statement is not yet available in the sources reviewed because the FY2026 annual report is pending.

Income statement

EBIT and EBITDA are analyst-computed: EBIT is pre-tax loss plus finance costs, and EBITDA is EBIT plus PPE and right-of-use depreciation.

Margins and growth (analyst-computed)

Revenue CAGR FY2022–FY2026: about 18.3% a year (analyst-computed: (19.679/10.048)^(1/4) − 1).

Commentary.

Revenue: Revenue nearly doubled from FY2022 to FY2025 on the post-COVID resumption of Singapore healthcare projects. The FY2023 MD&A notes projects returning to pre-pandemic levels, and the FY2025 commentary cites fewer but larger projects. FY2026 revenue fell 14.4% because customers undertook fewer construction projects (FY2026 MD&A).

Gross margin: Gross margin expanded from 30% to 46–48%. Management attributes this to higher-value, higher-margin projects from a more diversified customer base and to tighter cost control (FY2024 and FY2026 MD&A).

Cost structure: The cost base is the problem. Administrative expenses exceeded revenue every year and peaked at S$23.0 million in FY2025, driven by FinTech headcount, IT and licensing costs. The FY2026 cut of S$2.3 million (−9.8%) came alongside a fall in headcount from 113 to 103.

Finance costs: Finance costs more than doubled in FY2026 to S$0.37 million on interest on the US-dollar shareholder loan.

Inflection: The loss has stabilised in a S$12–14 million band but has never narrowed decisively. FY2026's attributable loss of S$12.2 million was the second-best of the five years.

Balance sheet

Debt composition: lease liabilities in every year, plus the HK$26 million convertible bond (fair value S$3.88 million in FY2025 and S$4.06 million in FY2026, current in FY2026) and the unsecured loan from Mr. Lin (S$12.62 million non-current in FY2025; S$11.15 million current in FY2026, due 15 May 2027 with a one-year extension option). No assets are pledged (FY2026 MD&A).

Commentary. The FY2024 balance-sheet spike to S$57.2 million was not an operating expansion. It reflected about S$23.4 million of client money in "amounts due to clients" and a matching receivable in the Trading and Asset Management business, which unwound in FY2025–FY2026.

Equity attributable to owners more than halved in FY2025 to S$13.0 million as losses outran a near-absence of new equity. In FY2026 it was partially rebuilt by the HK$76.8 million placing and the NCI capital injection into BG Ventures.

The Group switched from essentially debt-free to reliance on controlling-shareholder credit in June 2025. At 30 Jun 2026, S$15.2 million of the S$15.9 million total debt falls due within 12 months: the CB in February 2027 and the loan in May 2027. Against that, cash was S$27.6 million before the S$11.4 million BG Ventures commitment that settled in August 2026.

Cash flow

Columns run FY2022–FY2025 only, because FY2026 cash flow is not yet available in the sources reviewed.

Source: S&P Global Market Intelligence via StockAnalysis, last updated 30 Sep 2026.

The Company's own capex definition, which includes right-of-use additions and for FY2022 the property purchase, gives S$7.9 million in FY2022, S$0.4 million in FY2023, S$1.1 million in FY2024, S$0.9 million in FY2025 (PPE only) and S$0.3 million in FY2026 (PPE only), per the results announcements. FY2026 equity raised was about S$12.29 million net from the 26 Feb 2026 placing (FY2026 Note 17). No buybacks occurred in any year (results announcements).

Commentary. Free cash burn has been remarkably steady at S$10.5–15.0 million a year, about S$51.8 million cumulatively over FY2022–FY2025 (analyst-computed). It was funded by about S$36.1 million of equity over FY2022–FY2025, a further S$12.3 million in FY2026, and S$17.3 million of new debt in FY2025. The business has never been self-funding under current ownership.

Ratios (analyst-computed; year-end balances)

Non-meaningful ratios. These ratios are not meaningful in any year FY2022–FY2026 because EBITDA and EBIT were negative.

Commentary. Liquidity metrics weakened structurally. The current ratio fell from 6.0x in FY2023 to 1.5x in FY2026 as debt moved into current liabilities. Working-capital efficiency improved, with the cash conversion cycle down from about 99 days to 17–31 days, as supplier credit lengthened. That improvement is a modest positive inside an otherwise loss-dominated profile.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment revenue (SGD Mn)

Segment revenue (SGD Mn)FY2022FY2023FY2024FY2025FY2026

Engineering Business (SGD Mn)

10.04812.85817.14921.53718.522

FinTech Platform Business (SGD Mn)

00.5850.31300.002

Trading and Asset Management (SGD Mn)

000.9711.4411.156

Investment Holding / Others (SGD Mn)

00000

Total (SGD Mn)

10.04813.44318.43322.97719.679

Revenue by Segment and Segment Assets & Liabilities

Segment result (SGD Mn)FY2022FY2023FY2024FY2025FY2026

Engineering Business (SGD Mn)

2.2110.8691.2600.9200.069

FinTech Platform Business (SGD Mn)

-10.342-12.301-11.281-11.783-9.193

Trading and Asset Management (SGD Mn)

00-0.2410.3930.396

Investment Holding / Others (SGD Mn)

-3.012-3.365-2.809-3.468-3.795

Total segment results (SGD Mn)

-11.143-14.797-13.071-13.937-12.522

Segment Margins & Growth (%) and Revenue by Segment (%)

Metric (%)FY2022FY2023FY2024FY2025FY2026

Engineering segment margin (%)

22.06.87.34.30.4

Engineering revenue YoY growth (%)

028.033.425.6-14.0

Engineering share of group revenue (%)

100.095.693.093.794.1

T&AM segment margin (%)

00-24.827.334.3

T&AM share of group revenue (%)

005.36.35.9

FinTech share of group revenue (%)

04.41.700.01

Revenue by Segment and Segment Assets & Liabilities (Assets FY2025–Liabilities FY2026)

Segment (SGD Mn)Assets FY2025Assets FY2026Liabilities FY2025Liabilities FY2026

Engineering

15.90615.4447.1887.586

FinTech Platform

14.27116.1631.2820.919

Trading and Asset Management

6.1662.1395.2150.047

Others

8.04010.19517.73316.092

Total

44.38443.94131.41924.643

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue (SGD Mn)

10.04813.44318.43322.97719.679

Cost of services/sales (SGD Mn)

7.0198.9609.59613.80710.575

Gross profit (SGD Mn)

3.0294.4828.8379.1709.105

Other income (SGD Mn)

0.2570.5040.5690.4130.422

Other gains/(losses), net (SGD Mn)

-0.0620.0190.6260.036-0.542

Administrative expenses (SGD Mn)

13.95719.20822.47322.97420.717

Operating income, EBIT before finance costs (SGD Mn)

-10.732-14.203-12.441-13.354-11.733

Depreciation, PPE + right-of-use (SGD Mn)

0.8670.9461.0181.2471.250

EBITDA (SGD Mn)

-9.865-13.257-11.423-12.107-10.483

Finance costs (SGD Mn)

0.1530.0900.0610.1690.368

Pre-tax loss (SGD Mn)

-10.885-14.293-12.502-13.524-12.101

Income tax (SGD Mn)

-0.382-0.242-0.147-0.1040.038

Net loss (SGD Mn)

-11.267-14.535-12.649-13.628-12.063

Net loss attributable to owners (SGD Mn)

-11.267-14.533-12.648-13.627-12.191

EPS basic (S$ cents)

-1.25-1.47-1.20-1.27-1.11

EPS diluted (S$ cents)

-1.25-1.47-1.20-1.29-1.11

Dividends per share (S$ cents)

00000

Total staff costs (SGD Mn)

12.216.920.620.717.8

Margin Analysis (%)

Metric (%)FY2022FY2023FY2024FY2025FY2026

Gross margin (%)

30.133.347.939.946.3

Operating margin (%)

-106.8-105.7-67.5-58.1-59.6

EBITDA margin (%)

-98.2-98.6-62.0-52.7-53.3

Net margin, attributable (%)

-112.1-108.1-68.6-59.3-61.9

Admin expenses / revenue (%)

138.9142.9121.9100.0105.3

Revenue YoY growth (%)

033.837.124.6-14.4

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (SGD Mn)

33.44534.76157.21544.38443.941

Cash and bank balances (SGD Mn)

18.93219.15515.71618.45927.566

Trade receivables (SGD Mn)

3.2503.7443.4415.1235.087

Contract assets (SGD Mn)

2.5223.6454.4025.4223.045

Cryptocurrencies (SGD Mn)

0.0120.4401.3251.3120.824

Investment properties (SGD Mn)

5.2495.1124.9424.2934.039

Goodwill (SGD Mn)

000.0320.0320.032

Short-term debt incl. current leases, CB, current loans (SGD Mn)

0.8910.5270.3944.57015.819

Long-term debt incl. non-current leases and loans (SGD Mn)

0.4730.1280.29913.1650.099

Total debt (SGD Mn)

1.3640.6560.69317.73515.918

Net debt, negative = net cash (SGD Mn)

-17.568-18.499-15.023-0.724-11.648

Total liabilities (SGD Mn)

5.0034.70630.38731.41924.643

Equity attributable to owners (SGD Mn)

28.44330.05826.83112.97013.783

Non-controlling interests (SGD Mn)

-0.001-0.003-0.004-0.0045.514

Total equity (SGD Mn)

28.44230.05526.82812.96619.297

Working capital, net current assets (SGD Mn)

20.75622.90519.89318.65612.959

Cash Flow

MetricFY2022FY2023FY2024FY2025

Operating cash flow (SGD Mn)

-9.48-14.84-12.12-12.61

Capital expenditure, PPE (SGD Mn)

-1.02-0.20-0.60-0.92

Free cash flow (SGD Mn)

-10.50-15.04-12.72-13.53

Purchase of real estate (SGD Mn)

-5.16000

Equity issuance proceeds (SGD Mn)

10.9916.068.860.22

Net debt issued/(repaid) incl. leases (SGD Mn)

-0.37-0.74-0.6616.60

Dividends paid (SGD Mn)

0000

Share buybacks (SGD Mn)

0000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE, attributable loss / year-end owners' equity (%)

-39.6-48.3-47.1-105.1-88.4

ROA, net loss / total assets (%)

-33.7-41.8-22.1-30.7-27.5

ROIC, EBIT / (equity + debt − cash) (%)

-98.7-122.9-105.4-109.1-153.4

Current ratio (x)

5.66.01.72.01.5

Debt / equity, total debt / total equity (%)

4.82.22.6136.882.5

Gearing, company definition: interest-bearing liabilities / total assets (%)

4.11.91.231.227.0

Asset turnover, revenue / total assets (x)

0.300.390.320.520.45

DSO, trade receivables only (days)

118.1101.768.181.494.4

DPO, trade payables / cost of sales (days)

19.523.849.564.863.4

Cash conversion cycle, no inventory (days)

98.677.918.616.631.0

Financial Analysis

RatioAssessment

Net debt / EBITDA

Not meaningful. The Group was in net cash every year, with the minimum of S$0.7 million in FY2025

Interest coverage, EBIT / finance costs

Negative every year: about -70x in FY2022, -158x in FY2023, -203x in FY2024, -79x in FY2025 and -32x in FY2026

P/E

Not meaningful (loss-making)

Region revenue (SGD Mn)

Region revenue (SGD Mn)FY2022FY2023FY2024FY2025FY2026

Singapore (SGD Mn)

10.04812.85817.14921.53718.522

Hong Kong and others (SGD Mn)

00.5851.2841.4411.158

Mainland China (SGD Mn)

00000

Total (SGD Mn)

10.04813.44318.43322.97719.679

Geographic share and growth (%)

Geographic share and growth (%)FY2022FY2023FY2024FY2025FY2026

Singapore share (%)

10096939494

Singapore YoY growth (%)

028.033.425.6-14.0

Hong Kong and others YoY growth (%)

00119.612.2-19.6

Region non-current assets (SGD Mn)

Region non-current assets (SGD Mn)FY2022FY2023FY2024FY2025FY2026

Hong Kong and others (SGD Mn)

6.6846.4416.3616.3075.359

Mainland China (SGD Mn)

0.7120.2430.2520.2690.112

Singapore (SGD Mn)

0.5930.6210.6560.6410.696

Share Count (millions) and Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Shares in issue at FY end (millions)

960.001,050.031,076.081,077.751,141.75

Weighted average shares, basic (millions)

898.63991.811,052.471,076.761,099.66

Equity raised, gross (HKD Mn)

64.094.551.126.076.8

Placing / issue price (HKD)

0.401.052.002.501.20

Share Price & Returns

Reference pointPrice (HKD)Source

2021 change-of-control offer price

0.188

HKEX, 21 May 2021

8 Jul 2025

1.53

Stoxray

≈8 Nov 2025

≈1.59 (derived from TipRanks market cap HK$1.71bn ÷ 1,077.7m shares)

TipRanks (derived)

52-week range as of Nov 2025

1.20 – 2.37

TipRanks

30 Jul 2026

1.00

Lixinger

29 Sep 2026

0.74

StockAnalysis

30 Sep 2026

0.45 (−38.8%)

StockAnalysis

2 Oct 2026

0.28 (−38.9%)

StockAnalysis

5 Oct 2026

0.24 (−14.6%)

StockAnalysis

9 Oct 2026

0.255

StockAnalysis

Valuation Multiples

MultipleHKE HoldingsBasis

Market capitalisation

HK$291m / ≈S$47.5m

1,141.75m shares; S$0.163/HK$

Enterprise value (excl. NCI)

≈S$35.8m

Mcap + debt S$15.9m − cash S$27.6m

EV/Sales (FY2026)

≈1.8x

S$35.8m / S$19.7m

P/Sales (FY2026)

≈2.4x

S$47.5m / S$19.7m

P/B (owners' equity S$13.8m)

≈3.4x

—

Capital Instruments

InstrumentAmountRateMaturity

Unsecured loan from Lin Ho Man

S$11.15m (US$8.5m principal plus US$0.13m interest payable)

2.5% p.a.

15 May 2027 (one-year extension by mutual agreement)

Zero-coupon convertible bond (FVTPL)

S$4.06m fair value (HK$26m principal)

0%

19 Feb 2027; convertible at HK$2.50, currently far out of the money

Lease liabilities

S$0.70m

—

S$0.60m within 1 year

Analyst Conclusions

Management guidance

Guidance is qualitative only. Management intends to complete the FinTech disposal, redirect resources to Trading and Asset Management, and evaluate AI, healthcare and asset-light projects. It remains positive on Singapore healthcare-construction demand, including MRI shielding entry and new-hospital planning (FY2026 MD&A). No quantitative guidance is published, and there are no consensus forecasts.

Bull case

  1. The overhead cliff disappears. FinTech consumed about 45% of S$20.7m of administrative expenses (≈S$9.3m) and produced a S$9.2m segment loss in FY2026. Removing it could leave a residual group running near breakeven, with engineering contributing gross profit of about S$8–9m. That is analyst inference, and the "Others" overhead of S$3.8m remains.

  2. The balance sheet is rebuilt by the disposal. The stated aggregate consideration of HK$250.8m (≈S$40.9m), if realised in cash, would be close to the entire current market capitalisation of about S$47.5m. It would also cover the S$15.2m of 2027 maturities about 2.7 times.

  3. A structural healthcare backlog supports the core. Singapore's 2030 polyclinic and hospital programme, plus the imaging backlog, underpin multi-year demand for a specialist with 46% group gross margin.

Bear case

  1. Related-party value transfer. The FinTech assets were funded by minority-diluting placings: 55% of February 2026 proceeds (HK$41.8m allocated) went to FinTech only seven months before the sale to the controller. The terms assign HK$334.9m of loans for HK$250.8m. The market's 68% four-day decline signals that investors see unfavourable terms or uncertain settlement.

  2. The core business is shrinking and losing margin. Engineering revenue fell 14% in FY2026 and its segment margin collapsed to 0.4%. Customer concentration of about 73% leaves revenue hostage to a handful of tenders.

  3. The strategy is vague and capital may be misallocated again. "AI-related" and "asset-light" ambitions come without targets after five years of FinTech losses (≈S$55m). A further S$11.4m was committed to an undisclosed 2.29% minority stake. Repeated equity issuance has been the funding model.

Key catalysts and monitorables (next 12 months)

  • The disposal circular (by 31 Oct 2026): valuation, independent financial adviser opinion, payment terms and expected gain or loss.

  • The independent shareholder vote on the disposal, and whether consideration is settled in cash or by offset against the shareholder loan.

  • The AGM on 26 Nov 2026 and any general mandate for further issuance.

  • The H1 FY2027 interim results (around February 2027): residual-group cost base, engineering order intake and margin.

  • The refinancing or repayment of the CB (19 Feb 2027) and the shareholder loan (15 May 2027).

  • Disclosure of the BG Ventures investee and use of the HK$26.6m strategic-investment proceeds earmarked by 31 Dec 2026.

  • Further board, executive or auditor changes, and public-float compliance.

Analyst verdict

HKE Holdings is at an inflection, but the direction is not yet clear. The underlying operating franchise is real but small: a niche Singapore healthcare contractor. That business generated S$18.5 million of revenue in FY2026, consistently positive segment results and group gross margins in the mid-40s. Since 2021, however, the investment case has been subordinated to a Hong Kong FinTech venture. That venture absorbed about S$55 million of segment losses, drove five rounds of dilution and turned a debt-free balance sheet into one reliant on controlling-shareholder credit. It produced an SFC-licensed exchange with almost no revenue.

The September 2026 decision to sell the platform to the Chairman's own vehicles is, in isolation, financially rational: it removes the single largest source of cash burn. But governance optics dominate the market's response. The Group bought its asset-management arm from a substantial-shareholder-linked vendor in 2023. In 2026 it raised minority capital earmarked for FinTech and then sold FinTech to the controller months later. It has cycled through three auditors since 2023. The share price fall from HK$0.74 to HK$0.255 erased about two-thirds of market value in days. At about S$36 million of EV (pre-BG Ventures settlement), the market now ascribes little value to either the disposal proceeds or the engineering business.

The equity therefore behaves as a binary option on the disposal's terms and settlement mechanics. If consideration is received substantially in cash and the residual group's overhead falls in line with FinTech's exit, the current valuation looks dislocated relative to stated proceeds and net cash. If instead proceeds are offset, deferred or eroded by fresh strategic ventures, persistent losses will continue to consume equity. Our stance is speculative and governance-discounted: the stock should be monitored and not underwritten until the circular confirms valuation, cash settlement and a credible cost plan for the residual group.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleTenureBackground (from HKEX director announcements)

Mr. Lin Ho Man (連浩民)

Chairman and Executive Director; controlling shareholder

Chairman/NED from 1 Jun 2021; ED from 19 Jan 2022

Aged 28 at appointment in 2021, so about 33–34 now. Founder of Monmonkey Group Holdings. Community roles have included Tung Wah Group of Hospitals director (2021/22) and positions in Hong Kong youth and CPPCC-affiliated associations.

Mr. Koh Lee Huat (許利發)

Executive Director

Since listing (2018); CEO at IPO

Long-standing Hwa Koon management; pre-IPO shareholder

Mr. Cheng Yiu Mo (鄭耀武)

Non-executive Director

Since 19 Jan 2022

—

Mr. Lim Kai Jia Kesley (林凱佳)

Non-executive Director

Since 19 Jan 2022

—

Mr. Siu Man Ho Simon (蕭文豪)

INED

Since listing (2018)

Audit Committee member

Prof. Pong Kam Keung (龐錦強)

INED

Since listing (2018)

Audit Committee member

—

INED; Audit Committee Chairman

——

Ms. Lam Lam Nixie (林琳)

INED

Since 25 Apr 2025

—

Board & Management Changes

DateChangeSource

25 Apr 2025

Ms. Lam Lam Nixie appointed INED; a concurrent resignation recorded. Mr. Cheung Kwok Yan Wilfred, the former Audit Committee chair, no longer appears on the FY2026 board, so his departure around this date is inferred

Annual Report 2025 corporate information; FY2026 results

23 Jul 2025

Mr. Tsang Wing Fung resigned as Executive Director (ED since 2021)

Annual Report 2025; Interim Report 2026

1 Aug 2024 to 8 Jan 2026

Mr. Zhou Peng appointed and then resigned as Executive Director

FY2024 results; Interim Report 2026

30 Jun 2026

Company Secretary and Authorised Representative resigned and a replacement was appointed. The predecessor 何英傑 signed monthly returns to early 2026

etnet announcement list; monthly returns

Directors' Remuneration

Metric (SGD Mn)FY2025FY2026

Total directors' emoluments (SGD Mn)

2.0321.418

Share option expense, group (SGD Mn)

0.0840.075

Major Shareholders

HolderShares% of 1,141,746,668Source / note

Flourish Nation Enterprises Ltd (Lin Ho Man)

584,000,000 (last disclosed holding)

≈51.2% (analyst-computed if unchanged)

Acquired Apr 2021 (73% of 800 million shares); 60.83% of 960 million shares per HKEX 19 Jan 2022. CCASS data shows about 568 million shares (49.72%) held through a single broker participant as of 19 Aug 2026, which may represent the controlling stake

Mr. Lin Ho Man, share options

800,000 options (as of Jan 2022)

—

HKEX, 19 Jan 2022

Public float (residual)

≈48.8% if the controlling stake is unchanged

—

Analyst-computed

Institutional holders, top 10

Not publicly disclosed. No identifiable institutional holders were found; the register appears dominated by the controller and retail or brokerage nominees

—

CCASS snapshot (Lixinger)

Competitive Landscape

Key Competitors

Competitor / categoryRelevance

Specialist radiation-shielding contractors (Singapore SMEs)

Direct competitors in lead-lined rooms and bunkers

Global RF/MRI shielding specialists (e.g., ETS-Lindgren)

Competitors in MRI-room shielding, the market HKE plans to enter

Medical-equipment OEM turnkey programmes (imaging and radiotherapy vendors)

Can bundle room preparation with equipment supply

General healthcare fit-out and M&E contractors in Singapore

Compete for design-and-build packages

HKEX-listed small contractors (peer set used by data providers: Build King Holdings 240.HK, Able Engineering 1626.HK)

Valuation and size comparators, not direct competitors

Competitor Detail

MetricHKE Holdings (FY2026)

Revenue

S$19.7 million

Revenue growth

−14.4%

Gross margin

46.3%

Net margin

−61.9%

R&D intensity

Not disclosed (FinTech loss/revenue 46.7%)

Recent Developments

--

Company Snapshot

$15M

Revenue

103

Employees

1979

Founded

P.O. Box, Cayman Islands

Headquarters

SWOT Analysis

Strengths

  • Gross margin step-up: group gross margin rose from 30.1% (FY2022) to 46.3% (FY2026) on higher-value contracts (FY2026 MD&A).
  • Engineering has been profitable at the segment level for five straight years: S$2.2m in FY2022, S$0.9m in FY2023, S$1.3m in FY2024, S$0.9m in FY2025 and S$0.07m in FY2026.
  • Net cash position: S$27.6m of cash against S$15.9m of debt at 30 Jun 2026, giving net cash of S$11.6m.
  • Regulatory licences: BGE holds Type 1, Type 7 and VATP licences, and Monmonkey Group Asset Management holds Type 4 and Type 9.
  • Supportive controller: Mr. Lin provided a US$10m loan at 2.5% in June 2025 and is buying the loss-making FinTech unit.
  • Strong client receivable quality: no trade-receivable impairment was recognised in FY2022–FY2026, and the over-180-day bucket was only S$0.12m in FY2026.

Weaknesses

  • Chronic losses: S$11.3–14.5m of net loss in each of FY2022–FY2026, about S$64m cumulative (analyst-computed).
  • Overhead exceeds revenue: administrative expenses were 105.3% of revenue in FY2026 and 142.9% in FY2023.
  • Customer concentration: four customers were about 73% of FY2026 revenue.
  • Engineering margin erosion: the segment margin fell from 22.0% in FY2022 to 0.4% in FY2026.
  • Near-term maturity wall: S$15.2m of CB and shareholder loan falls due between February and May 2027.
  • Governance churn: three auditors since 2023, two Executive Director departures in six months (Jul 2025 and Jan 2026), and repeated connected-party transactions.

Opportunities

  • Singapore healthcare pipeline: 6 new polyclinics, 6 redevelopments and new hospitals at Bedok North and Tengah by about 2030 (FY2026 MD&A).
  • MRI shielding entry: this addresses a 3-month MRI backlog (FY2026 MD&A).
  • Freed-up overhead: removing a segment that consumed about 45% of administrative expenses could move group profitability toward breakeven.
  • Trading and Asset Management momentum: segment profit of S$0.40m in FY2026, with fee income rising (asset management fees +63% year on year).
  • Strategic stake upside: the 2.29% BG Ventures stake (≈S$11.4m) could produce gains if the investee performs; the investee is undisclosed.

Threats

  • Tender cyclicality: FY2026 revenue fell 14% when client projects declined.
  • VA market volatility and competition from 11 other licensed VATPs; management cites stricter licensing standards.
  • Disposal execution risk: independent shareholder approval is required, and the price reaction (−68% from 30 Sep to 5 Oct 2026) signals investor scepticism.
  • Currency mismatch: proceeds are held in HK$ and US$, while operations run in S$ and no hedging is used (FY2026 MD&A).
  • Further dilution: five equity raises since 2021 and 28.6m options outstanding.
  • Crypto and fair-value volatility: a cryptocurrency fair-value loss of S$0.36m and a CB fair-value loss of S$0.12m in FY2026.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
25 Apr 2025Board refresh: Ms. Lam Lam Nixie appointed INED, with a concurrent director resignationGovernance renewal; audit committee reconstituted
17 Jun 2025SFC grants BGE Type 1, Type 7 and AMLO VATP licencesKey milestone of the FinTech thesis; BGE became Hong Kong's 11th licensed VATP
18 Jun 2025Voluntary announcement of the licencesMarket disclosure
Jun 2025About US$10 million unsecured loan drawn from Lin Ho ManFirst material borrowing; dependence on the controller
23 Jul 2025Executive Director Tsang Wing Fung resignsLoss of a long-tenured executive
Sep 2025Board meeting notice for FY2025 results (29 Sep 2025)Routine
29 Sep 2025FY2025 results: revenue S$23.0 million (+24.6%); attributable loss S$13.6 million; no dividendRevenue peak; losses persist
23 Oct 2025Annual Report 2025 publishedFull disclosure including the ESG report
Nov 2025Shares trade around HK$1.59 (market cap HK$1.71 billion per TipRanks, ≈8 Nov 2025)Pre-collapse valuation reference
2 Jan 2026December 2025 monthly return: 1,077,746,668 shares; 28,617,328 options; CB unconvertedCapital structure stable
8 Jan 2026Executive Director Zhou Peng resigns after 17 monthsFurther executive attrition
Jan 2026BGE VA trading platform officially launched; OTC desk offeredCommercial launch
3 Feb 2026January 2026 monthly return: 40,000 options cancelledRoutine
4 Feb 2026Placing of 64 million new shares at HK$1.20 announced under the general mandateFurther dilution (≈5.9%) to fund FinTech
10 Feb 2026Board meeting notice for interim results (25 Feb 2026)Routine
16 Feb 2026Voluntary announcement on BGE launch and platform/OTC/custody features; references MMKPositioning communication
Feb 2026BG Ventures agrees to subscribe 2.29% of an unnamed investee for about RMB60 millionNew strategic investment of about S$11.4 million
25 Feb 2026H1 FY2026 interim results; TTM revenue about S$22.9 million and TTM loss about S$10.8 million per Simply Wall StLosses narrowing at the half-year
26 Feb 2026Placing completed; net proceeds about HK$76.0 millionLiquidity boost
18 Mar 2026Interim Report 2026 publishedDisclosure
29 May 2026Circular and EGM notice for the revised MMK VA cooperation framework (to Jun 2029)Connected-party growth plan for BGE
22 Jun 2026EGM held; poll results announcedShareholder vote on the CCT framework
30 Jun 2026Company Secretary and Authorised Representative replacedAdministrative change
Jul–Aug 2026Shares drift from about HK$1.00 to HK$0.90 on thin volumePre-results weakness
Aug 2026BG Ventures investment completedCash outflow of about S$11.4 million after the balance-sheet date
–Auditor transitions to Moore CPA LimitedThird audit firm since 2023
29 Sep 2026Major and connected disposal agreements for True Victor and Wonder Time (FinTech Platform Business)Strategic reversal; related-party exit
30 Sep 2026FY2026 results: revenue S$19.7 million (−14.4%); loss S$12.1 million; cash S$27.6 million; no dividendSecond consecutive year without growth in profitability
30 Sep–5 Oct 2026Shares fall from HK$0.74 to HK$0.24 (≈−68%) on 2.4–2.8 million shares per day versus typical sub-0.5 millionSevere market rejection of the results and disposal package
By 31 Oct 2026 (expected)Circular on the disposal to be despatchedKey information event
26 Nov 2026 (scheduled)AGM; register closed 23–26 Nov 2026Governance event

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Income Statement: Revenue & Gross Profit: Revenue rose from SGD 10 Mn in FY2022 to SGD 19.7 Mn in FY2026.
HKE Holdings Limited — Income Statement: Revenue & Gross Profit
Series (SGD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue1013.418.42319.7
Cost of services/sales799.613.810.6
Gross profit34.58.89.29.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. HKE Holdings, FY2026 Annual Results Announcement (30 Sep 2026) (pdf.dfcfw.com)
  2. HKE Holdings, FY2024 Annual Results Announcement (26 Sep 2024) (www1.hkexnews.hk)
  3. HKE Holdings, FY2023 Annual Results Announcement (28 Sep 2023) (www1.hkexnews.hk)
  4. HKE Holdings, Annual Report 2025 (www1.hkexnews.hk)
  5. HKE Holdings, Annual Report 2024 (www1.hkexnews.hk)
  6. HKE Holdings, Annual Report 2022 (www1.hkexnews.hk)
  7. HKE Holdings, Interim Report 2026 (hkexnews.hk)
  8. HKE Holdings, Interim Report 2025 (www1.hkexnews.hk)
  9. HKE Holdings, Interim Results H1 FY2025 (www1.hkexnews.hk)
  10. HKE Holdings, Interim Results H1 FY2024 (www1.hkexnews.hk)
  11. HKE Holdings, Interim Report 2023 (www1.hkexnews.hk)
  12. HKE Holdings, Profit warning FY2022 (www1.hkexnews.hk)
  13. HKE Holdings, Profit warning FY2023 (www1.hkexnews.hk)
  14. HKE Holdings, BGE licence announcement (18 Jun 2025) (www1.hkexnews.hk)
  15. HKE Holdings, Voluntary announcement on BGE launch (16 Feb 2026) (www1.hkexnews.hk)
  16. HKE Holdings, 2024 placing completion (www1.hkexnews.hk)
  17. HKE Holdings, 2023 placing use-of-proceeds supplement (www1.hkexnews.hk)
  18. HKE Holdings / Flourish Nation, offer documents (Apr–Jun 2021) · www1.hkexnews.hk · www1.hkexnews.hk · www1.hkexnews.hk · www1.hkexnews.hk · www1.hkexnews.hk
  19. HKE Holdings, Director announcements (19 Jan 2022) · www1.hkexnews.hk
  20. HKE Holdings, Property acquisition completion (22 Dec 2021) (www1.hkexnews.hk)
  21. HKE Holdings, Eagle Fortitude-related announcements (2019) · www1.hkexnews.hk
  22. HKE Holdings, Interim Report 2019 and Annual Report 2019 · www1.hkexnews.hk
  23. HKE Holdings, Board meeting notice (Sep 2018) (www1.hkexnews.hk)
  24. SFC, Lists of virtual asset trading platforms (sfc.hk)
  25. Fintech News HK, BGE VATP licence (fintechnews.hk)
  26. Fintech News HK, Licensed crypto exchanges in Hong Kong (fintechnews.hk)
  27. Cointelegraph, Victory Fintech approval (cointelegraph.com)
  28. Bulletin Express / Tiger, MMK EGM circular (itiger.com)
  29. Bulletin Express / Tiger, 2025 Annual Report highlights (itiger.com)
  30. Bulletin Express / Tiger, FY2025 results (itiger.com)
  31. Bulletin Express / Tiger, Monthly returns Jan 2026 and Dec 2025 · itiger.com
  32. Bulletin Express / Tiger, Interim board meeting notice (Feb 2026) (itiger.com)
  33. RTTNews, FY2026 results (rttnews.com)
  34. StockAnalysis (S&P Global Market Intelligence), cash flow, balance sheet and price history · stockanalysis.com · stockanalysis.com
  35. TipRanks, quote, statistics and announcements · tipranks.com · tipranks.com
  36. Simply Wall St (simplywall.st)
  37. Stockopedia (stockopedia.com)
  38. Stoxray (stoxray.com)
  39. Lixinger, CCASS broker holdings and valuation history · lixinger.com
  40. etnet, announcement list (etnet.com.hk)
  41. Guantao (IPO counsel note) (guantao.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.